With Activist Investors Looming, Genzyme Takes Preventive Steps
This article was originally published in The Pink Sheet Daily
Executive Summary
Mutual cooperation agreement with top institutional investor and hiring of a new head of global product quality may be intended to stave off a potential proxy fight.
You may also be interested in...
As Chinese and Indian Markets Expand, Young American Drug Outfits Should Hold Onto Ex-U.S. Rights, Says Genzyme Leader
BOSTON - Despite conventional wisdom and Wall Street's old-fashioned point of view, young American companies starting out should think long and hard before giving up ex-U.S. rights to their discoveries, the top executives of Massachusetts biotechs Genzyme and Biogen Idec advise
Hang On To Those Ex-U.S. Rights, Biotech Veterans Termeer And Mullen Advise Start-Ups
The two 30-year industry veterans talked about lessons learned, regulatory climate change and health care reform at MassBio's annual meeting in Boston.
Hang On To Those Ex-U.S. Rights, Biotech Veterans Termeer And Mullen Advise Start-Ups
The two 30-year industry veterans talked about lessons learned, regulatory climate change and health care reform at MassBio's annual meeting in Boston.